An in vitro and in vivo investigation into the suitability of compression coated tablets of indomethacin for the treatment of rheumatoid arthritis which follow circadian rhythms

Drug Development and Industrial Pharmacy

Volumn 39, Issue 3, 2013, Pages 447-456

  Songa, Ambedkar Sunil ^a   Meka, Venkata Srikanth ^a   Nali, Sreenivasa Rao ^a   Kolapalli, Venkata Ramana Murthy ^a  

^a ANDHRA UNIVERSITY   (India)

Author keywords

Chronotherapeutic drug delivery system; Circadian rhythms; Compression coated tablets; Pharmacokinetic evaluation; Sucrose fatty acid ester 1815

Indexed keywords

INDOMETACIN; MACROGOL;

ADULT; ARTICLE; CIRCADIAN RHYTHM; DIFFERENTIAL SCANNING CALORIMETRY; DISPERSION; DRUG COATING; DRUG FORMULATION; DRUG SOLUBILITY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFRARED SPECTROSCOPY; MALE; RHEUMATOID ARTHRITIS; SCANNING ELECTRON MICROSCOPY; TABLET COMPRESSION; WEIGHT; X RAY DIFFRACTION;

ADMINISTRATION, ORAL; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, RHEUMATOID; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; DRUG CHRONOTHERAPY; DRUG DELIVERY SYSTEMS; HUMANS; INDOMETHACIN; TABLETS;

EID: 84873626437     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2012.662509     Document Type: Article

References (30)

1. Sangalli ME, Maroni A, Zema L, Busetti C, Giordano F, Gazzaniga A. (2001). In vitro and in vivo evaluation of an oral system for time and/or site-specific drug delivery. J Control Release, 73:103-110.
2. Brayden DJ. (2003). Controlled release technologies for drug delivery. Drug Discov Today, 8:976-978.
3. Paolisso G, Scheen AJ, Giugliano D, Sgambato S, Albert A, Varricchio M et al. (1991). Pulsatile insulin delivery has greater metabolic effects than continuous hormone administration in man: importance of pulse frequency. J Clin Endocrinol Metab, 72:607-615.
4. White WB, Black HR, Weber MA, Elliott WJ, Bryzinski B, Fakouhi TD. (1998). Comparison of effects of controlled onset extended release verapamil at bedtime and nifedipine gastrointestinal therapeutic system on arising on early morning blood pressure, heart rate, and the heart rate-blood pressure product. Am J Cardiol, 81:424-431.
5. Sunil SA, Srikanth MV, Sreenivasa Rao N, Uhumwangho MU, Latha K, Ramana Murthy KV. (2011). Chronotherapeutic drug delivery systems-an approach to circadian rhythms diseases. Curr Drug Deliv, 8:622-633.
6. Sangalli ME, Maroni A, Busetti C, Zema L, Giordano F, Gazzaniga A. (1999). In vitro and in vivo evaluation of oral systems for time and site specific delivery of drugs (Chronotopic technology). Boll Chim Farm, 138:68-73.
7. Leslie S. (1986). The Contin delivery system: dosing considerations. J Allergy Clin Immunol, 78:768-773.
8. Washington N, Wilson CG. (2006). Can oral controlled drug delivery meet the challenges posed by chronotherapeutics Drug Deliv Technol, 6:1-5.
9. Descombes S, Bonnet AM, Gasser UE, Thalamas C, Dingemanse J, Arnulf I et al. (2001). Dual-release formulation, a novel principle in L-dopa treatment of Parkinson's disease. Neurology, 56:1239-1242.
10. Lee BJ, Cui JH, Kim TW, Heo MY, Kim CK. (1998). Biphasic release characteristics of dual drug-loaded alginate beads. Arch Pharm Res, 21:645-650.
11. Smith RB, Kroboth PD, Folan MM, Kroboth FJ, Rosanske TW. (1993). Design and pharmacodynamic evaluation of novel dual release formulations of triazolam. Int J Clin Pharmacol Ther Toxicol, 31: 422-429.
12. Otsuka M, Matsuda Y. (1994). Controlled drug release of highly water-soluble pentoxifylline from time-limit disintegration-type wax matrix tablets. Pharm Res, 11:351-354.
13. Pozzi F, Furlani P, Gazzaniga A. (1994). The time clock system: a new oral dosage form for fast and complete release of drug after a predetermined lag time. J Contr Rel, 31:99-108.
14. Krishnaiah YSR, Satyanarayana S, Rama Prasad YV, Narasimha Rao S. (1998). Evaluation of guar gum as a compression coat for drug targeting to colon. Int J Pharm, 71:137-146
15. Krishnaiah YS, Satyanarayana S, Prasad YV. (1999). Studies of guar gum compression-coated 5-aminosalicylic acid tablets for colon-specific drug delivery. Drug Dev Ind Pharm, 25: 651-657.
16. Fernandez-Hervas MJ, Fell JT. (1998). Pectin:chitosan mixtures as coatings for colon-specific drug delivery: an in vitro evaluation. Int J Pharm, 169:115-119.
17. Ahrabi SF, Madsen G, Dyrstad K, Sande SA, Graffner C. (2000). Development of pectin matrix tablets for colonic delivery of model drug ropivacaine. Eur J Pharm Sci, 10:43-52.
18. Turkoglu M, Takka S, Baran H, Sakr A. (1999). Pectin hydroxyl propyl methyl cellulose drug delivery system for colon targeting. Pharm Pharmacol, 51:154.
19. Turkoglu M, Ugurlu T. (2002). In vitro evaluation of pectin-HPMC compression coated 5-aminosalicylic acid tablets for colonic delivery. Eur J Pharm Biopharm, 53:65-73.
20. Ugurlu T, Turkoglu M, Gurer US, Akarsu BG. (2007). Colonic delivery of compression coated nisin tablets using pectin/HPMC polymer mixture. Eur J Pharm Biopharm, 67:202-210.
21. SCOTT JT. (1960). Morning stiffness in rheumatoid arthritis. Ann Rheum Dis, 19:361-368.
22. Kowanko IC, Pownall R, Knapp MS, Swannell AJ, Mahoney PG. (1981). Circadian variations in the signs and symptoms of rheumatoid arthritis and in the therapeutic effectiveness of flurbiprofen at different times of day. Br J Clin Pharmacol, 11:477-484.
23. Javadzadeh Y, Siahi MR, Asnaashari S, Nokhodchi A. (2007). Liquisolid technique as a tool for enhancement of poorly watersoluble drugs and evaluation of their physicochemical properties. Acta Pharm, 57:99-109.
24. Sawada T, Kondo H, Nakashima H, Sako K, Hayashi M. (2004). Time-release compression-coated core tablet containing nifedipine for chronopharmacotherapy. Int J Pharm, 280:103-111.
25. IP2010. Uniformity of weight of single-dose preparations and Uniformity of content of single-dose preparations. The Indian Pharmacopoeia Commission, Ghaziabad, India. 2010;187-192.
26. ZelkR, Orb A, Segh K. (2006). Tracking of the physical ageing of amorphous pharmaceutical polymeric excipients by positron annihilation spectroscopy. J Pharm Biomed Anal, 40:249-254.
27. Shigeoka T, Izawa O, Kitazawa K, Yamauchi F, Murata T. (1984). Studies on the metabolic fate of sucrose esters in rats. Food Chem Toxicol, 22:409-414.
28. Husband FA, Samey DB, Barnard MJ, Wilde PJ. (1998). Comparison of foaming and interfacial properties of pure sucrose monolaurates, dilaurate and commercial preparations. Food Hydrocolloid,12:237-244.
29. Tual A, Bourles E, Barey P, Houdoux A, Desprairies M, Courthaudon JL. (2006). Effect of surfactant sucrose ester on physical properties of dairy whipped emulsions in relation to those of O/W interfacial layers. J Colloid Interface Sci, 295:495-503.
30. ICH. Harmonised tripartite guideline: Stability testing of new drug substances and products ICH Q1A(R2). ICH Expert Working Group, Europe, Japan and USA. February 2003.